Hanns-Ulrich Marschall

List of Publications by Year in Descending Order

198 papers	17,056 citations	63 h-index	129 g-index
223 ext. papers	20,583 ext. citations	7.8 avg, IF	6.39 L-index

#	Paper	IF	Citations
198	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.. *Journal of Hepatology*, **2022**,	13.4	1
197	Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders.. *Biochemical Society Transactions*, **2022**,	5.1	2
196	Silencing of STE20-type kinase STK25 in human aortic endothelial and smooth muscle cells is atheroprotective.. *Communications Biology*, **2022**, 5, 379	6.7	1
195	Recent advances on FXR-targeting therapeutics. *Molecular and Cellular Endocrinology*, **2022**, 552, 111678	4.4	3
194	Antagonizing STK25 Signaling Suppresses the Development of Hepatocellular Carcinoma Through Targeting Metabolic, Inflammatory, and Pro-Oncogenic Pathways. *Cellular and Molecular Gastroenterology and Hepatology*, **2021**,	7.9	2
193	STE20-type kinase TAOK3 regulates hepatic lipid partitioning. *Molecular Metabolism*, **2021**, 54, 101353	8.8	1
192	STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes. *Hepatology Communications*, **2021**, 5, 1183-1200	6	4
191	Silencing of STE20-type kinase MST3 in mice with antisense oligonucleotide treatment ameliorates diet-induced nonalcoholic fatty liver disease. *FASEB Journal*, **2021**, 35, e21567	0.9	5
190	Meta-analysis and Consolidation of Farnesoid X Receptor Chromatin Immunoprecipitation Sequencing Data Across Different Species and Conditions. *Hepatology Communications*, **2021**, 5, 1721-1736	6	2
189	Extrahepatic autoimmune diseases in primary biliary cholangitis: Prevalence and significance for clinical presentation and disease outcome. *Journal of Gastroenterology and Hepatology (Australia)*, **2021**, 36, 936-942	4	7
188	Bile acid biosynthesis in Smith-Lemli-Opitz syndrome bypassing cholesterol: Potential importance of pathway intermediates. *Journal of Steroid Biochemistry and Molecular Biology*, **2021**, 206, 105794	5.1	8
187	Fetal cardiac dysfunction in intrahepatic cholestasis of pregnancy is associated with elevated serum bile acid concentrations. *Journal of Hepatology*, **2021**, 74, 1087-1096	13.4	9
186	A multi-centre, open label, randomised, parallel-group, superiority Trial to compare the efficacy of URsodeoxycholic acid with RIFampicin in the management of women with severe early onset Intrahepatic Cholestasis of pregnancy: the TURRIFIC randomised trial. *BMC Pregnancy and Childbirth* , **2021**, 21, 51	3.2	6
185	Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers. *Liver International*, **2021**, 41, 545-553	7.9	4
184	Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 547-558	18.8	21
183	FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. *Cell Metabolism*, **2021**, 33, 1671-1684.e4	24.6	25
182	The BACH project protocol: an international multicentre total Bile Acid Comparison and Harmonisation project and sub-study of the TURRIFIC randomised trial. *Clinical Chemistry and Laboratory Medicine*, **2021**, 59, 1921-1929	5.9	2

181	Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling. *Nature Metabolism*, **2021**, 3, 1228-1241	14.6	8
180	Glycemic Control and Metabolic Adaptation in Response to High-Fat versus High-Carbohydrate Diets-Data from a Randomized Cross-Over Study in Healthy Subjects. *Nutrients*, **2021**, 13,	6.7	1
179	Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. *Liver International*, **2020**, 40, 1366-1377	7.9	7
178	Ursodeoxycholic acid enriches intestinal bile salt hydrolase-expressing Bacteroidetes in cholestatic pregnancy. *Scientific Reports*, **2020**, 10, 3895	4.9	11
177	Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia. *American Journal of Physiology - Renal Physiology*, **2020**, 319, G197-G211	5.1	1
176	Ursodeoxycholic acid improves feto-placental and offspring metabolic outcomes in hypercholanemic pregnancy. *Scientific Reports*, **2020**, 10, 10361	4.9	4
175	FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. *Journal of Hepatology*, **2020**, 72, 1122-1131	13.4	22
174	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2295-2304.e2	6.9	5
173	The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non-alcoholic fatty liver disease. *Molecular Systems Biology*, **2020**, 16, e9495	12.2	16
172	Depletion of protein kinase STK25 ameliorates renal lipotoxicity and protects against diabetic kidney disease. *JCI Insight*, **2020**, 5,	9.9	7
171	Lipid droplet-associated kinase STK25 regulates peroxisomal activity and metabolic stress response in steatotic liver. *Journal of Lipid Research*, **2020**, 61, 178-191	6.3	13
170	Maternal glucose homeostasis is impaired in mouse models of gestational cholestasis. *Scientific Reports*, **2020**, 10, 11523	4.9	5
169	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 179-187.e6	6.9	24
168	Obeticholic acid may increase the risk of gallstone formation in susceptible patients. *Journal of Hepatology*, **2019**, 71, 986-991	13.4	28
167	Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans. *FASEB Journal*, **2019**, 33, 9974-9989	0.9	9
166	Reply. *Hepatology Communications*, **2019**, 3, 848	6	1
165	Germline selection shapes human mitochondrial DNA diversity. *Science*, **2019**, 364,	33.3	105
164	Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis. *Hepatology*, **2019**, 70, 276-293	11.2	17

163	Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. *Gut*, **2019**, 68, 1477-1492	19.2	55
162	Incidence, prevalence, and outcome of primary biliary cholangitis in a nationwide Swedish population-based cohort. *Scientific Reports*, **2019**, 9, 11525	4.9	24
161	AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. *Metabolism: Clinical and Experimental*, **2019**, 99, 67-80	12.7	22
160	Ursodeoxycholic acid for intrahepatic cholestasis in pregnancy. *Lancet, The*, **2019**, 394, 810-812	40	4
159	Muscle performance and fatigue in compensated chronic liver disease. *Scandinavian Journal of Gastroenterology*, **2019**, 54, 925-933	2.4	2
158	Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes. *American Journal of Physiology - Endocrinology and Metabolism*, **2019**, 317, E399-E410	6	9
157	Enzymatic quantification of total serum bile acids as a monitoring strategy for women with intrahepatic cholestasis of pregnancy receiving ursodeoxycholic acid treatment: a cohort study. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2019**, 126, 1633-1640	3.7	18
156	Associations between Dietary Patterns and Bile Acids-Results from a Cross-Sectional Study in Vegans and Omnivores. *Nutrients*, **2019**, 12,	6.7	30
155	Gut pathobionts as triggers for liver diseases. *Nature Microbiology*, **2019**, 4, 380-381	26.6	1
154	Future Medical Treatment of PSC. *Current Hepatology Reports*, **2019**, 18, 96-106	1	5
153	Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. *Lancet, The*, **2019**, 393, 899-909	40	166
152	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. *Database: the Journal of Biological Databases and Curation*, **2019**, 2019,	5	4
151	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet, The*, **2019**, 394, 2184-2196	40	425
150	Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis. *American Journal of Gastroenterology*, **2019**, 114, 1101-1108	0.7	22
149	Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease. *Cellular and Molecular Gastroenterology and Hepatology*, **2019**, 7, 597-618	7.9	20
148	A Comprehensive FXR Signaling Atlas Derived from Pooled ChIP-seq Data. *Studies in Health Technology and Informatics*, **2019**, 260, 105-112	0.5	1
147	Plasma Bile Acid Concentrations in Humans: Suggestions for Presentation in Tabular Form. *Hepatology*, **2018**, 68, 787	11.2	4
146	Colesevelam attenuates cholestatic liver and bile duct injury in mice by modulating composition, signalling and excretion of faecal bile acids. *Gut*, **2018**, 67, 1683-1691	19.2	35

145	An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans. *Cell Metabolism*, **2018**, 27, 559-571.e5	24.6	189
144	Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. *Scientific Reports*, **2018**, 8, 6658	4.9	37
143	Pregnancy outcome in women undergoing liver biopsy during pregnancy: A nationwide population-based cohort study. *Hepatology*, **2018**, 68, 625-633	11.2	12
142	High clinical impact and diagnostic accuracy of EUS-guided biopsy sampling of subepithelial lesions: a prospective, comparative study. *Surgical Endoscopy and Other Interventional Techniques*, **2018**, 32, 1304-1313	5.2	21
141	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. *Hepatology*, **2018**, 67, 1890-1902	11.2	139
140	Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. *Liver International*, **2018**, 38, 523-531	7.9	18
139	No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. *Gastroenterology*, **2018**, 155, 752-759.e5	13.3	44
138	Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial. *BMC Gastroenterology*, **2018**, 18, 76	3	24
137	Ensuring timely treatment of patients with primary biliary cholangitis. *The Lancet Gastroenterology and Hepatology*, **2018**, 3, 591-593	18.8	1
136	Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH. *Frontiers in Pharmacology*, **2018**, 9, 931	5.6	28
135	The Importance of Gestation-Adjusted Birthweight Centile in Assessment of Fetal Growth in Metabolic Conditions. *JCRPE Journal of Clinical Research in Pediatric Endocrinology*, **2018**, 10, 299-300	1.9	
134	Role of Bile Acids in Metabolic Control. *Trends in Endocrinology and Metabolism*, **2018**, 29, 31-41	8.8	178
133	Serine/threonine protein kinase 25 antisense oligonucleotide treatment reverses glucose intolerance, insulin resistance, and nonalcoholic fatty liver disease in mice. *Hepatology Communications*, **2018**, 2, 69-83	6	23
132	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. *Gut*, **2018**, 67, 1517-1524	19.2	28
131	Outcomes of Pregnancy in Mothers With Cirrhosis: A National Population-Based Cohort Study of 1.3 Million Pregnancies. *Hepatology Communications*, **2018**, 2, 1299-1305	6	30
130	Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action. *Journal of Clinical Apheresis*, **2018**, 33, 638-644	3.2	4
129	STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 1723-1737	9.4	7
128	The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. *Gut*, **2017**, 66, 611-619	19.2	216

127	The 35-year odyssey of beta blockers in cirrhosis: any gender difference in sight?. *Pharmacological Research*, **2017**, 119, 20-26	10.2	4
126	The Effects of Liver Disease in Pregnancy on Mother and Child **2017**, 81-96		
125	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. *Gastroenterology*, **2017**, 152, 1975-1984.e8	13.3	219
124	NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. *Journal of Hepatology*, **2017**, 67, 110-119	13.4	30
123	Personal model-assisted identification of NAD and glutathione metabolism as intervention target in NAFLD. *Molecular Systems Biology*, **2017**, 13, 916	12.2	92
122	Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling. *Digestive Diseases*, **2017**, 35, 246-250	3.2	53
121	Protein kinase STK25 aggravates the severity of non-alcoholic fatty pancreas disease in mice. *Journal of Endocrinology*, **2017**, 234, 15-27	4.7	17
120	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. *Journal of Hepatology*, **2017**, 67, 549-558	13.4	138
119	Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 1022-1028	2.4	25
118	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1950-1956.e1	6.9	54
117	Cyp3a11 is not essential for the formation of murine bile acids. *Biochemistry and Biophysics Reports*, **2017**, 10, 70-75	2.2	10
116	Metabolic preconditioning protects BSEP/ABCB11 mice against cholestatic liver injury. *Journal of Hepatology*, **2017**, 66, 95-101	13.4	37
115	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. *Nature Genetics*, **2017**, 49, 269-273	36.3	140
114	Induction of farnesoid X receptor signaling in germ-free mice colonized with a human microbiota. *Journal of Lipid Research*, **2017**, 58, 412-419	6.3	41
113	Why Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?. *Current Hepatology Reports*, **2017**, 16, 119-123	1	11
112	Epidermal growth factor signaling protects from cholestatic liver injury and fibrosis. *Journal of Molecular Medicine*, **2017**, 95, 109-117	5.5	12
111	Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. *Scandinavian Journal of Gastroenterology*, **2017**, 52, 159-165	2.4	35
110	Histological improvement of liver fibrosis in well-treated patients with autoimmune hepatitis: A cohort study. *Medicine (United States)*, **2017**, 96, e7708	1.8	6

109	Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus. *World Journal of Gastroenterology*, **2017**, 23, 3174-3183	5.6	2
108	STK25 is a critical determinant in nonalcoholic steatohepatitis. *FASEB Journal*, **2016**, 30, 3628-3643	0.9	30
107	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *New England Journal of Medicine*, **2016**, 375, 631-43	59.2	574
106	Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. *Journal of Hepatology*, **2016**, 64, 674-81	13.4	99
105	Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metabolism*, **2016**, 24, 41-50	24.6	1022
104	The ileal bile acid transporter inhibitor A4250 decreases serum bile acids by interrupting the enterohepatic circulation. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 303-10	6.1	54
103	Pregnancy course in patients with intrahepatic cholestasis of pregnancy treated with very low doses of ursodeoxycholic acid. *Scandinavian Journal of Gastroenterology*, **2016**, 51, 256	2.4	2
102	Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease. *Oncotarget*, **2016**, 7, 86985-86998	3.3	10
101	Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. *Hepatology*, **2016**, 64, 189-99	11.2	81
100	Serum bile acids and GLP-1 decrease following telemetric induced weight loss: results of a randomized controlled trial. *Scientific Reports*, **2016**, 6, 30173	4.9	17
99	Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum. *Hepatology*, **2016**, 63, 1287-98	11.2	56
98	Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. *Nature Genetics*, **2016**, 48, 1396-1406	36.3	369
97	Letter: ileal bile acid transporter inhibition- is there a potential for drug-drug interaction? Authors' reply. *Alimentary Pharmacology and Therapeutics*, **2016**, 43, 751	6.1	
96	Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: A population-based cohort study. *Journal of Hepatology*, **2015**, 63, 456-61	13.4	67
95	Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy. *European Journal of Obstetrics, Gynecology and Reproductive Biology*, **2015**, 189, 59-63	2.4	63
94	Angiotensin II exerts dual actions on sodium-glucose transporter 1-mediated transport in the human jejunal mucosa. *Scandinavian Journal of Gastroenterology*, **2015**, 50, 1068-75	2.4	6
93	Management of intrahepatic cholestasis of pregnancy. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 1273-9	4.2	20
92	Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. *Journal of Hepatology*, **2015**, 62, 1398-404	13.4	168

91	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. *Gastroenterology*, **2015**, 148, 751-61.e8	13.3	381
90	A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. *American Journal of Gastroenterology*, **2014**, 109, 76-84	0.7	84
89	Characterization of animal models for primary sclerosing cholangitis (PSC). *Journal of Hepatology*, **2014**, 60, 1290-303	13.4	96
88	Variant adiponutrin confers genetic protection against cholestatic itch. *Scientific Reports*, **2014**, 4, 6374	4.9	6
87	Reply: To PMID 23564560. *Hepatology*, **2014**, 60, 1452	11.2	
86	The reversed feto-maternal bile acid gradient in intrahepatic cholestasis of pregnancy is corrected by ursodeoxycholic acid. *PLoS ONE*, **2014**, 9, e83828	3.7	58
85	Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Gastroenterology*, **2013**, 145, 574-82.e1	13.3	635
84	Enhanced fasting and post-prandial plasma bile acid responses after Roux-en-Y gastric bypass surgery. *Scandinavian Journal of Gastroenterology*, **2013**, 48, 1257-64	2.4	66
83	Endoscopic assessment and grading of Barrett's esophagus using magnification endoscopy and narrow band imaging: impact of structured learning and experience on the accuracy of the Amsterdam classification system. *Scandinavian Journal of Gastroenterology*, **2013**, 48, 160-7	2.4	24
82	Risks of emergency cesarean section and fetal asphyxia after induction of labor in intrahepatic cholestasis of pregnancy: a hospital-based retrospective cohort study. *Sexual and Reproductive Healthcare*, **2013**, 4, 17-22	2.4	16
81	Genome-wide association analysis in primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4. *Hepatology*, **2013**, 58, 1074-83	11.2	118
80	Intrahepatic cholestasis of pregnancy and associated adverse pregnancy and fetal outcomes: a 12-year population-based cohort study. *BJOG: an International Journal of Obstetrics and Gynaecology*, **2013**, 120, 717-23	3.7	133
79	Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: a population-based cohort study. *Hepatology*, **2013**, 58, 1385-91	11.2	127
78	Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. *Cell Metabolism*, **2013**, 17, 225-35	24.6	1204
77	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. *Nature Genetics*, **2013**, 45, 670-5	36.3	267
76	Gallstone disease in Swedish twins is associated with the Gilbert variant of UGT1A1. *Liver International*, **2013**, 33, 904-8	7.9	8
75	Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype. *Hepatology*, **2013**, 57, 716-26	11.2	104
74	Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. *Journal of Hepatology*, **2012**, 57, 366-75	13.4	173

73	Stereological assessment of placental morphology in intrahepatic cholestasis of pregnancy. *Placenta*, **2012**, 33, 914-8	3.4	25
72	Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. *Digestion*, **2012**, 86, 244-9	3.6	5
71	Endoscopic assessment and grading of Barrett's esophagus using magnification endoscopy and narrow-band imaging: accuracy and interobserver agreement of different classification systems (with videos). *Gastrointestinal Endoscopy*, **2011**, 73, 7-14	5.2	61
70	Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1688-97	4.7	106
69	Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. *Digestive Diseases*, **2011**, 29, 117-8	3.2	6
68	Nutritional regulation of bile acid metabolism is associated with improved pathological characteristics of the metabolic syndrome. *Journal of Biological Chemistry*, **2011**, 286, 28382-95	5.4	51
67	Gallstone disease in Swedish twins: risk is associated with ABCG8 D19H genotype. *Journal of Internal Medicine*, **2010**, 268, 279-85	10.8	51
66	Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites. *Journal of Biological Chemistry*, **2010**, 285, 16504-12	5.4	48
65	The genetic background of gallstone formation: an update. *Biochemical and Biophysical Research Communications*, **2010**, 396, 58-62	3.4	25
64	Decreased 1,25-dihydroxy vitamin D levels in women with intrahepatic cholestasis of pregnancy. *Acta Obstetricia Et Gynecologica Scandinavica*, **2010**, 89, 1420-3	3.8	26
63	Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. *Hepatology*, **2010**, 52, 197-203	11.2	74
62	Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. *Gut*, **2009**, 58, 537-44	19.2	152
61	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. *Hepatology*, **2009**, 49, 1972-81	11.2	110
60	Fish protein hydrolysate elevates plasma bile acids and reduces visceral adipose tissue mass in rats. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2009**, 1791, 254-62	5	84
59	Role of short-chain hydroxyacyl CoA dehydrogenases in SCHAD deficiency. *Biochemical and Biophysical Research Communications*, **2008**, 368, 6-11	3.4	27
58	Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with decreased progesterone disulphates in urine. *Hepatology*, **2008**, 47, 544-51	11.2	84
57	Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. *Molecular Pharmaceutics*, **2007**, 4, 895-910	5.6	21
56	Gallstone disease. *Journal of Internal Medicine*, **2007**, 261, 529-42	10.8	111

55	Body mass index, alcohol, tobacco and symptomatic gallstone disease: a Swedish twin study. *Journal of Internal Medicine*, **2007**, 262, 581-7	10.8	38
54	Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. *Gut*, **2007**, 56, 265-70	19.2	98
53	A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. *American Journal of Pathology*, **2007**, 171, 525-36	5.8	227
52	Hep27, a member of the short-chain dehydrogenase/reductase family, is an NADPH-dependent dicarbonyl reductase expressed in vascular endothelial tissue. *Cellular and Molecular Life Sciences*, **2006**, 63, 1205-13	10.3	35
51	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. *American Journal of Physiology - Renal Physiology*, **2006**, 290, G923-32	5.1	141
50	Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. *Journal of Lipid Research*, **2006**, 47, 582-92	6.3	87
49	Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation*, **2006**, 81, 1390-7	1.8	896
48	Chronic liver disease is triggered by taurine transporter knockout in the mouse. *FASEB Journal*, **2006**, 20, 574-6	0.9	89
47	Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. *American Journal of Pathology*, **2006**, 168, 410-22	5.8	134
46	24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. *Gastroenterology*, **2006**, 130, 465-81	13.3	250
45	Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. *Molecular Pharmaceutics*, **2006**, 3, 231-51	5.6	242
44	Mice lacking Mrp3 (Abcc3) have normal bile salt transport, but altered hepatic transport of endogenous glucuronides. *Journal of Hepatology*, **2006**, 44, 768-75	13.4	150
43	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. *Journal of Hepatology*, **2006**, 44, 243-5	13.4	29
42	Analysis of ileal sodium/bile acid cotransporter and related nuclear receptor genes in a family with multiple cases of idiopathic bile acid malabsorption. *World Journal of Gastroenterology*, **2006**, 12, 7710-4	5.6	26
41	Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. *Gastroenterology*, **2005**, 129, 476-85	13.3	234
40	Oncosis represents the main type of cell death in mouse models of cholestasis. *Journal of Hepatology*, **2005**, 42, 378-85	13.4	74
39	High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. *Gastroenterology*, **2005**, 129, 1464-72	13.3	276
38	Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats. *Transplant International*, **2005**, 17, 804-9	3	4

37	Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs. *Hepatology*, **2005**, 41, 1138-43	11.2	179
36	CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. *Hepatology*, **2005**, 42, 420-30	11.2	257
35	Reply:. *Hepatology*, **2005**, 42, 738-738	11.2	3
34	Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. *Hepatology*, **2005**, 42, 1399-405	11.2	189
33	Enteral donor pre-treatment with ursodeoxycholic acid protects the liver against ischaemia-reperfusion injury in rats. *Transplant International*, **2004**, 17, 804-809	3	9
32	Ursodeoxycholic acid does not affect ethinylestradiol bioavailability in women taking oral contraceptives. *European Journal of Clinical Pharmacology*, **2004**, 60, 481-7	2.8	3
31	Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. *Hepatology*, **2004**, 40, 467-74	11.2	562
30	Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. *Gastroenterology*, **2004**, 127, 261-74	13.3	456
29	Expanded substrate screenings of human and Drosophila type 10 17beta-hydroxysteroid dehydrogenases (HSDs) reveal multiple specificities in bile acid and steroid hormone metabolism: characterization of multifunctional 3alpha/7alpha/7beta/17beta/20beta/21-HSD. *Biochemical Journal*, **2003**, 376, 49-60	3.8	71
28	Intrahepatic Cholestasis of Pregnancy. *Current Treatment Options in Gastroenterology*, **2003**, 6, 123-132	2.5	37
27	Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. *Gastroenterology*, **2003**, 125, 825-38	13.3	235
26	Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. *Journal of Hepatology*, **2003**, 38, 717-27	13.4	241
25	Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. *Journal of Hepatology*, **2003**, 39, 480-8	13.4	159
24	Increase in renal glutathione in cholestatic liver disease is due to a direct effect of bile acids. *American Journal of Physiology - Renal Physiology*, **2002**, 283, F1281-9	4.3	6
23	Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. *Gastroenterology*, **2002**, 123, 1238-51	13.3	249
22	Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats. *Biochimica Et Biophysica Acta - General Subjects*, **2001**, 1526, 44-52	4	11
21	Primary cultures of human hepatocytes but not HepG2 hepatoblastoma cells are suitable for the study of glycosidic conjugation of bile acids. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2001**, 1530, 155-61	5	5
20	Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. *Journal of Lipid Research*, **2001**, 42, 735-742	6.3	27

19	Human liver class I alcohol dehydrogenase gammagamma isozyme: the sole cytosolic 3beta-hydroxysteroid dehydrogenase of iso bile acids. *Hepatology*, **2000**, 31, 990-6	11.2	23
18	Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management. *Journal of Hepatology*, **2000**, 33, 1012-21	13.4	375
17	Response. *Gastrointestinal Endoscopy*, **1999**, 49, 818-9	5.2	
16	Bioinformatics in studies of SDR and MDR enzymes. *Advances in Experimental Medicine and Biology*, **1999**, 463, 373-7	3.6	6
15	Life-threatening complications of nasogastric administration of polyethylene glycol-electrolyte solutions (Golytely) for bowel cleansing. *Gastrointestinal Endoscopy*, **1998**, 47, 408-10	5.2	63
14	Long-term extracorporeal bilirubin elimination: A case report on cascade resin plasmaperfusion. *Blood Purification*, **1998**, 16, 341-8	3.1	12
13	Study of human isoursodeoxycholic acid metabolism. *Journal of Hepatology*, **1997**, 26, 863-70	13.4	14
12	Stimulation of bile acid 6 alpha-hydroxylation by rifampin. *Journal of Hepatology*, **1996**, 24, 713-8	13.4	71
11	The influence of rifampin treatment on caffeine clearance in healthy man. *Journal of Hepatology*, **1995**, 22, 78-81	13.4	31
10	A new subgroup of lectin-bound biliary proteins binds to cholesterol crystals, modifies crystal morphology, and inhibits cholesterol crystallization. *Journal of Clinical Investigation*, **1995**, 96, 3009-15	15.9	22
9	The major metabolites of ursodeoxycholic acid in human urine are conjugated with N-acetylglucosamine. *Hepatology*, **1994**, 20, 845-53	11.2	38
8	Portal vein thrombosis after occlusion of a transjugular intrahepatic portosystemic shunt: recanalization with the impeller catheter. *Journal of Vascular and Interventional Radiology*, **1994**, 5, 467-71	2.4	21
7	Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 beta-hydroxylated bile acids in humans. *Journal of Clinical Investigation*, **1992**, 89, 1981-7	15.9	74
6	Urinary excretion of bile acid glucosides and glucuronides in extrahepatic cholestasis. *Hepatology*, **1991**, 13, 656-662	11.2	30
5	Synthesis of 13C-labeled chenodeoxycholic, hyodeoxycholic, and ursodeoxycholic acids for the study of bile acid metabolism in liver disease. *Clinica Chimica Acta*, **1991**, 203, 77-89	6.2	8
4	Bile acid N-acetylglucosaminides. Formation by microsomal N-acetylglucosaminyltransferases in human liver and kidney. *FEBS Letters*, **1990**, 270, 11-4	3.8	14
3	Isolation of bile acid glucosides and N-acetylglucosaminides from human urine by ion-exchange chromatography and reversed-phase high-performance liquid chromatography. *Journal of Chromatography A*, **1988**, 452, 459-68	4.5	30
2	Evidence for bile acid glucosides as normal constituents in human urine. *FEBS Letters*, **1987**, 213, 411-4	3.8	41

1 6 alpha-glucuronidation of hyodeoxycholic acid by human liver, kidney and small bowel microsomes. *Lipids and Lipid Metabolism*, **1987**, 921, 392-7 34